Emerging Markets Regulatory Tracker: China Biosimilar Guidance Finalized
This article was originally published in PharmAsia News
China’s FDA has now issued the final version of its guidance on biosimilars that was issued for comment last year, taking into account some of the feedback it received.
You may also be interested in...
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.